Evidence map›Paper›PMID 38205204›Full record

ArticleTranslational lung cancer research2023

Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (

Jiaqi Li, Kuofang Huang, Hao Ji, Jialin Qian, Haijiao Lu, Yanan Zhang, Alessandro Russo, Atocha Romero, Edyta Maria Urbanska, Fabrizio Tabbò and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. ALK-tyrosine kinase inhibitor intrinsic resistance due toTranslational lung cancer research · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Jiaqi Li *Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Kuofang Huang *Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hao Ji *Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jialin QianDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Haijiao LuDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yanan ZhangDepartment of Exosome, 3D Medicines Inc., Shanghai, China.
Alessandro RussoMedical Oncology Unit, Department of Onco-Hematology, Papardo Hospital, Messina, Italy.
Atocha RomeroMedical Oncology Department, Hospital Universitario Puerta de Hierro de Majadahonda, Madrid, Spain.
Edyta Maria UrbanskaDepartment of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Fabrizio TabbòOncology Unit, Department of Medicine, Michele and Pietro Ferrero Hospital, Verduno, Italy.
Xiaoyu ZhaoDepartment of Exosome, 3D Medicines Inc., Shanghai, China.
Tianqing ChuDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai Chest Hospital · CNShanghai Jiao Tong University · CNAzienda Ospedaliera Ospedali Riuniti Papardo Piemonte · ITHospital Universitario Puerta de Hierro Majadahonda · ESOspedale San Pietro Fatebenefratelli · ITRigshospitalet · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Alectinib significantly improves survival of non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase ( Methods: Using the electronic medical record system, we reviewed in terms of clinical and pathological features patients with advanced (IIIB/IV stage) Results: A total of 66 patients were enrolled in the study, and 17 types of Conclusions: In this study, the efficacy of alectinib in different types of

Indexed as

alectinibanaplastic lymphoma kinase (ALK)chromosomal rearrangementsco-mutated genesNon-small cell lung cancer (NSCLC)

Identifiers

PMID38205204
PMCPMC10775000
OpenAlexW4390237970

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.